STEVENSON, Md., Aug. 9, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Prosensa Holding N.V. ("Prosensa" or the "Company") (Nasdaq: RNA ) common stock pursuant and/or traceable to the Registration Statement and Prospectus ("Offering Documents") issued in connection with the Company's initial public offering ("IPO") on or about June 28, 2013.
If you have suffered a loss from investment in Prosensa common stock in connection with the Company's IPO on or about June 28, 2013, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html . You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than September 16, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period.
The complaint accuses the defendants of violations of the Securities Act of 1933 by virtue of the defendants' failure to disclose that the Offering Documents contained materially false and/or misleading statements and/or omitted material information concerning the development status of the drug drisapersen, the drug's Phase II and Phase III clinical studies, and its prospects for regulatory approval. According to the complaint, following the Company's September 20, 2013 announcement that the drug had not met the primary endpoint in the Phase III study, the value of Prosensa shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616
